Replies to post #156537 on Biotech Values

[oc631]

HCV patients and their physicians are accustomed to waiting for better treatment options. Sofo/Riba will be the first oral treatment approved in GT2 patients. Sure GT3 patients can go off-label but this doesn't mean the FDA is going to sign off on the pooled data. What oral therapy offers is better tolerability but this isn't going to come at the expense of dramatically increasing the number of patients that fail therapy.



For the sickest patients the "new" option will be Sofo/PegRiba. The interferon-intolerant or unwilling patients will go off-label or continue to wait.